Abstract: A pneumatic tire with a noise damper has a noise damper made of porous resin foam and arranged on a tread inner surface. The noise damper is formed by a single annular body extending continuously in a tire circumferential direction. The noise damper has a core density in a range of from 35 to 65 kg/m3 and an overall density in a range of from 50 to 105 kg/m3. A maximum height of the noise damper from the tread inner surface is in a range of from 12 to 30 mm.

Abstract: The present invention provides a combination of an antibody binding to a fibroblast growth factor receptor, and another agent.

Abstract: The present invention is related to a method for the production of polyurethane foam, comprising the steps of: providing an isocyanate-reactive component A comprising a polyol component A1 which further comprises a physical blowing agent T; combining at least the isocyanate-reactive component A and an isocyanate component B, thereby obtaining a polyurethane reaction mixture; providing the polyurethane reaction mixture in a cavity (11); and reducing the pressure within the cavity (11) to a pressure lower than ambient pressure; characterized in that the cavity (11) is ventilated to ambient pressure before the gel time of the polyurethane reaction mixture is reached.

Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.

Abstract: The present invention is related to a method for the production of polyurethane foam, comprising the steps of: (1) providing an isocyanate-reactive component A comprising a polyol component A1 which further comprises a physical blowing agent T; (2) combining at least the isocyanate-reactive component A and an isocyanate component B, thereby obtaining a polyurethane reaction mixture; (3) providing the polyurethane reaction mixture in a cavity (11); and (4) reducing the pressure within the cavity (11) to a pressure lower than ambient pressure. The method is characterized in that the cavity (11) is ventilated to ambient pressure before the gel time of the polyurethane reaction mixture is reached.

Abstract: The present invention relates to an antibody having a therapeutic effect on a tumor. That is, the invention relates to an antibody which binds to B7-H3 to exhibit an antitumor activity. An object of the invention is to provide a pharmaceutical having a therapeutic effect on a tumor. By obtaining an anti-B7-H3 antibody which binds to B7-H3 to exhibit an antitumor activity, a pharmaceutical composition for treating a tumor comprising the antibody and the like are obtained.

Abstract: The present invention provides a combination of an antibody binding to a fibroblast growth factor receptor, and another agent.

Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.

Abstract: An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment.

Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.

Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Abstract: The present invention is related to a method for the production of polyurethane foam, comprising the steps of: providing an isocyanate-reactive component A comprising a polyol component A1 which comprises a physical blowing agent T; combining at least the isocyanate-reactive component A and an isocyanate component B, thereby obtaining a polyurethane reaction mixture; providing the polyurethane reaction mixture in a cavity (11); and reducing the pressure within the cavity (11) to a pressure lower than ambient pressure; characterized in that the physical blowing agent T is present in the isocyanate-reactive component A in the form of an emulsion with the polyol component A1 constituting the continuous phase and droplets of the physical blowing agent T the dispersed phase of the emulsion, wherein the average size of the droplets of the physical blowing agent T is ?0.1 ?m to ?20 ?m, the droplet size being determined by using an optical microscope operating in bright field transmission mode.

Abstract: The present invention is related to a method for the production of polyurethane foam, comprising the steps of: providing an isocyanate-reactive component A comprising a polyol component A1 which further comprises a physical blowing agent T; combining at least the isocyanate-reactive component A and an isocyanate component B, thereby obtaining a polyurethane reaction mixture; providing the polyurethane reaction mixture in a cavity (11); and reducing the pressure within the cavity (11) to a pressure lower than ambient pressure; characterized in that the cavity (11) is ventilated to ambient pressure before the gel time of the polyurethane reaction mixture is reached.

Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.

Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Abstract: Problem to Be Solved It is intended to provide an antibody having an inhibitory activity against cell malignant transformation and/or tumor cell growth, etc. Solution The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Abstract: An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment.

Abstract: Problem to Be Solved It is intended to provide an antibody having an inhibitory activity against cell malignant transformation and/or tumor cell growth, etc. Solution The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Abstract: Methods comprising: providing an aromatic polyisocyanate and a polyol; and reacting the aromatic polyisocyanate and the polyol in the presence of a blowing agent and a catalyst to form a rigid polyurethane foam; wherein the blowing agent comprises water and a hydrocarbon having 3 to 8 carbon atoms; and wherein the polyol comprises a mixture of two or more polyether polyols according to formula (1): wherein each R independently represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms and n represents an integer of 0 to 5; the mixture of polyether polyols having a mean functionality of 4.5 or more; and wherein the mixture of polyether polyols comprises 50 to 70% by weight of a compound of formula (1) wherein n=0 is and 30 to 50% by weight of a compound of formula (1) wherein n?1; and wherein the mixture of polyether polyols comprises 2.5% by weight or more a compound of formula (1) wherein n=4, all percentages by weight based on the mixture of polyether polyol.